Reactive dose escalation of infliximab in patients with Crohn's disease in TAILORIX leads to improved outcomes

被引：0
|
作者：
Dreesen, E. [1 ]
Laharie, D. [2 ]
Lambrecht, G. [3 ]
Bossuyt, P. [4 ]
Buisson, A. [5 ]
Filippi, J. [6 ]
Van Hootegem, P. [7 ]
D'Haens, G. [8 ]
Vermeire, S. [9 ,10 ]
Gils, A. [1 ]
机构：
[1] Katholieke Univ Leuven, Dept Pharmaceut & Pharmacol Sci, Leuven, Belgium
[2] Hosp Haut Leveque, Bordeaux, France
[3] Damiaan Hosp, Oostende, Belgium
[4] Imelda Hosp, Bonheiden, Belgium
[5] Hosp Estaing, Clermont Ferrand, France
[6] Hosp Archet, Nice, France
[7] Sint Lucas Hosp, Brugge, Belgium
[8] Acad Med Ctr, Amsterdam, Netherlands
[9] Univ Hosp Leuven, Dept Gastroenterol & Hepatol, Leuven, Belgium
[10] Katholieke Univ Leuven, Dept Chron Dis Metab & Ageing, Leuven, Belgium
来源：
JOURNAL OF CROHNS & COLITIS | 2018年 / 12卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P572
引用
收藏
页码：S396 / S397
页数：3
相关论文
共 50 条
  • [41] Long term outcomes following de-escalation of dose-intensified ustekinumab in patients with Crohn's disease
    Demase, K.
    Smith, R. L.
    Luber, R.
    Taylor, K. M.
    Ward, M. G.
    Sparrow, M. P.
    Little, R. D.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1317 - I1317
  • [42] Ustekinumab Dose Escalation Is Effective in Treatment of Crohn's Disease
    Cohen, Erica
    Ha, Christina
    Syal, Gaurav
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2019, 114 : S384 - S385
  • [43] Predictors of adalimumab dose escalation in patients with crohn's disease at a tertiary referral center
    Cohen, Russell D.
    Lewis, Jeffrey R.
    Turner, Hannah
    Harrell, Laura E.
    Hanauer, Stephen B.
    Rubin, David T.
    INFLAMMATORY BOWEL DISEASES, 2012, 18 (01) : 10 - 16
  • [44] Effect of Ustekinumab Dose Escalation on Recapturing Clinical Response in Patients With Crohn's Disease
    Bundschuh, Mark
    McDonough, Gregory
    Kumar, Priyanka
    Kozuch, Patricia
    Shivashankar, Raina
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2019, 114 : S452 - S452
  • [45] Predictors and Timing of Adalimumab (ADA) Dose Escalation in Patients with Crohn's Disease (CD)
    Cohen, Russell D.
    Lewis, Jeffrey R.
    Turner, Hannah
    Hanauer, Stephen B.
    Rubin, David T.
    GASTROENTEROLOGY, 2009, 136 (05) : A652 - A652
  • [46] Rate of Ustekinumab Dose Escalation in Patients With Crohn's Disease Who Had a History of Anti-TNF Dose Escalation
    Sun, Kelly
    Manski, Scott
    Crawford, Albert
    Shivashankar, Raina
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (12S) : S5 - S5
  • [47] Infliximab dose intensification in patients with crohn's disease and ulcerative colitis: associated costs
    Taxonera, Carlos
    Olivares, David
    Mendoza, Juanl
    Caas, Mercedes
    Diaz-Rubio, Manuel
    Rey, Enrique
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2013, 28 : 812 - 813
  • [48] Increasing the infliximab dose is beneficial in Crohn's disease patients who responded to a lower dose and relapsed
    Menachem, Y
    Avidan, B
    Lavy, A
    Lang, A
    Bardan, E
    Fidder, H
    Bar-Meir, S
    Chowers, Y
    DIGESTION, 2005, 72 (2-3) : 124 - 128
  • [49] Ustekinumab use in Crohn's disease: effectiveness of dose escalation
    Greenup, A.
    Rosenfeld, G.
    Bressler, B.
    JOURNAL OF CROHNS & COLITIS, 2017, 11 : S400 - S400
  • [50] Better off NaiVE: Predictors of Adalimumab Dose Escalation in Patients With Crohn's Disease
    Moncrief, Karli
    Steinhart, A. Hillary
    Croitoru, Ken
    Newman, Alvin
    Nguyen, Geoffrey C.
    Xu, Wei
    Silverberg, Mark S.
    GASTROENTEROLOGY, 2012, 142 (05) : S359 - S359
12345